NEWTOWN, PA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced that it has repurchased an aggregate of 1,604,676 shares of Forian common stock in a privately negotiated transaction at redemption price of $2.15 per share for an aggregate purchase price of approximately $3.45 million. The redeemed shares were cancelled and retired and returned to authorized and unissued shares.
About Forian
Forian provides a unique suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences and healthcare payer and provider segments. For more information, please visit the Company’s website at www.forian.com.
Media and Investor Contact:
forian.com/investors
This email address is being protected from spambots. You need JavaScript enabled to view it.
267-225-6263
| Last Trade: | US$2.08 |
| Daily Change: | -0.10 -4.59 |
| Daily Volume: | 483,360 |
| Market Cap: | US$64.630M |
November 13, 2024 August 14, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
